LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.07 -2.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.95

Max

3.14

Pagrindiniai rodikliai
By Trading Economics
Pajamos	12M -47M
Darbuotojai	142
EBITDA	9.5M -49M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+217.81% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-144M 961M
Ankstesnė atidarymo kaina	5.3
Ankstesnė uždarymo kaina	3.07

Naujienos nuotaikos

By Acuity

25%

75%

61 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-14 22:44; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026-05-14 22:27; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026-05-14 22:12; UTC

Uždarbis

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026-05-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

LVMH to Sell Marc Jacobs

2026-05-15 00:00; UTC

Uždarbis

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026-05-14 23:57; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026-05-14 23:56; UTC

Rinkos pokalbiai

Gold Prices Rise on Strong Demand -- Market Talk

2026-05-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026-05-14 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026-05-14 23:47; UTC

Uždarbis

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026-05-14 23:47; UTC

Uždarbis

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026-05-14 23:46; UTC

Uždarbis

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026-05-14 23:28; UTC

Rinkos pokalbiai

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026-05-14 23:00; UTC

Rinkos pokalbiai

Australia's One Nation Party Leads In The Polls -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026-05-14 22:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-14 22:35; UTC

Rinkos pokalbiai

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026-05-14 22:11; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026-05-14 22:06; UTC

Rinkos pokalbiai

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026-05-14 22:04; UTC

Uždarbis

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026-05-14 22:00; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q EPS 18c >NU

2026-05-14 21:55; UTC

Uždarbis

Nu Holdings 1Q Rev $4.97B >NU

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

217.81% į viršų

12 mėnesių prognozė

Vidutinis 10.17 USD 217.81%

Aukščiausias 16 USD

Žemiausias 7 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

61 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.